The present application relates to compositions which influence the central nervous system and which are especially useful in the treatment of hyperkinesis and rigidity. These compositions contain as active ingredient 1,3-dimethyl-5-aminoadamantane in the form of the free base or a pharmaceutically-acceptable salt thereof, together with a methylxanthine compound, e.g., caffeine or theophylline, in an amount up to about fifteen milligrams of the methylxanthine compound per each milligram of the 1,3-dimethyl-5-aminoadamantane compound. These compositions are useful in the treatment of central nervous system disorders, particularly of Parkinson's disease, depressions, spasticity, rigidity, hyperkinesis, and the like. The compositions possess unpredictable beneficial properties of a synergistic nature. The application also relates to the treatment of such central nervous system ailments or conditions with a combination of the said two active agents either concurrently or together in the same dosage form or unit.
展开▼